- Home
- NGNE vs SAGE Comparison
NGNE vs SAGE Comparison
Compare NGNE & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- SAGE
- Stock Information
- Founded
- NGNE 2003
- SAGE 2010
- Country
- NGNE United States
- SAGE United States
- Employees
- NGNE N/A
- SAGE N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- NGNE Health Care
- SAGE Health Care
- Exchange
- NGNE Nasdaq
- SAGE Nasdaq
- Market Cap
- NGNE 471.1M
- SAGE 462.2M
- IPO Year
- NGNE N/A
- SAGE 2014
- Fundamental
- Price
- NGNE $70.19
- SAGE $6.26
- Analyst Decision
- NGNE Strong Buy
- SAGE Hold
- Analyst Count
- NGNE 6
- SAGE 20
- Target Price
- NGNE $49.00
- SAGE $12.89
- AVG Volume (30 Days)
- NGNE 166.4K
- SAGE 766.2K
- Earning Date
- NGNE 11-15-2024
- SAGE 10-29-2024
- Dividend Yield
- NGNE N/A
- SAGE N/A
- EPS Growth
- NGNE N/A
- SAGE N/A
- EPS
- NGNE 0.18
- SAGE N/A
- Revenue
- NGNE $925,000.00
- SAGE $106,399,000.00
- Revenue This Year
- NGNE N/A
- SAGE N/A
- Revenue Next Year
- NGNE N/A
- SAGE $126.69
- P/E Ratio
- NGNE $380.69
- SAGE N/A
- Revenue Growth
- NGNE N/A
- SAGE 837.60
- 52 Week Low
- NGNE $12.49
- SAGE $5.64
- 52 Week High
- NGNE $73.59
- SAGE $28.26
- Technical
- Relative Strength Index (RSI)
- NGNE 69.32
- SAGE 41.29
- Support Level
- NGNE $42.23
- SAGE $5.64
- Resistance Level
- NGNE $66.36
- SAGE $6.44
- Average True Range (ATR)
- NGNE 4.50
- SAGE 0.52
- MACD
- NGNE 1.51
- SAGE -0.15
- Stochastic Oscillator
- NGNE 65.72
- SAGE 22.22
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.